



Please Direct All Correspondence to Customer Number 20995

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Wen, et al.  
 App. No : 10/665,203  
 Filed : September 18, 2003  
 For : METHOD OF INHIBITING CHOROIDAL  
       NEOVASCULARIZATION  
 Examiner : Zohreh A. Fay  
 Art Unit : 1618

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 19, 2006

(Date)

Ned A. Israelson, Reg. No. 29,655

**Mail Stop Amendment**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 73 references.
  - (X) Enclosing 33 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.



Ned A. Israelson  
 Registration No. 29,655  
 Attorney of Record  
 Customer No. 20,995  
 (619) 235-8550

2305406:sad  
 011906

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/



## INFORMATION DISCLOSURE STATEMENT

Applicant : Wen, et al.  
 App. No : 10/665,203  
 Filed : September 18, 2003  
 For : METHOD OF INHIBITING  
       CHOROIDAL  
       NEOVASCULARIZATION  
 Examiner : Zohreh A. Fay  
 Art Unit : 1618

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 19, 2006

(Date)

Ned A. Israelson, Reg. No. 29,655

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 73 references to be considered by the Examiner. Also enclosed are 33 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

  
 Ned A. Israelson  
 Registration No. 29,655  
 Attorney of Record  
 Customer No. 20,995  
 (619) 235-8550

Dated: 1-19-06

2302707:sad  
 011906

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/665,203
(Multiple sheets used when necessary)		Filing Date	September 18, 2003
		First Named Inventor	Rong Wen
		Art Unit	1618
JAN 30 2006 SHEET 1 OF 4		Examiner	Zohreh A. Fay
		Attorney Docket No.	MACUS.002A

U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant
	1	2003-0027744	02-06-2003	M. Dana
	2	2004-0092435	05-13-2004	Peyman
	3	5,011,844	04-30-1991	Fehr
	4	5,100,899	03-31-1992	Calne
	5	5,189,042	02-23-1993	Goulet, et al.
	6	5,192,773	03-09-1993	Armistead
	7	5,258,389	11-02-1993	Goulet, et al.
	8	5,368,865	11-29-1994	Asakura, et al.
	9	5,378,475	01-03-1995	Smith, et al.
	10	5,387,589	02-07-1995	Kulkarni
	11	5,457,111	10-10-1995	Luly, et al.
	12	5,514,686	05-07-1996	Mochizuki
	13	5,527,907	06-18-1996	Or, et al.
	14	5,532,248	07-02-1996	Goulet, et al.
	15	5,621,108	04-15-1997	Smith, III et al.
	16	5,672,605	09-30-1997	Or, et al.
	17	5,773,019	06-30-1998	Ashton, et al.
	18	6,015,815	01-18-2000	Mollison
	19	6,329,386	12-11-2002	Mollison
	20	6,376,517	04-23-2002	Ross, et al.
	21	6,399,629 B1	06-04-2002	Chamberland et al.
	22	6,440,990	08-27-2002	Cottens, et al.
	23	6,534,693	03-18-2003	Fischell, et al.
	24	6,576,224	06-10-2003	Osbakken et al.
	25	6,632,836	10-14-2003	Baker, et al.
	26	6,699,493	03-02-2004	Wong
	27	6,713,081	03-30-2004	Robinson et al
	28	6,812,220	11-02-2004	Jackson, et al.
	29	6,872,383	03-29-2005	Ueno

Examiner Signature	/Zohreh Fay (11/11/2011)	Date Considered
--------------------	--------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a checkmark in this statement when the designated Dated Form is attached.

ALL REFERENCES CONSIDERED EXCEPT THOSE LINED THROUGH. /ZF/

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application No.</b>	10/665,203
<i>(Multiple sheets used when necessary)</i>		<b>Filing Date</b>	September 18, 2003
		<b>First Named Inventor</b>	Rong Wen
		<b>Art Unit</b>	1618
<b>SHEET 2 OF 4</b>		<b>Examiner</b>	Zohreh A. Fay
		<b>Attorney Docket No.</b>	MACUS.002A

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials	Cite No.	Document Number <i>Number - Kind Code (if known)</i> Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
30		6,890,546	09-05-2002	Mollison, et al.	
31		US 2003/0031631	02-13-2003	Osbakken et al.	
32		US 2003/0077297	04-24-2003	Chen et al.	
33		US 2003/0190286	10-09-2003	Dugger et al.	
34		US 2004/0018228	01-29-2004	Fischell et al.	
35		US 2004/0057958	03-25-2004	Waggoner et al.	
36		US 2004/0234611	11-25-2004	Ahlheim et al.	
37		US 2005/0025810	02-03-2005	Peyman	
38		US 2005/0048123	03-03-2005	Su et al.	
39		US 2005/0123605	06-09-2005	Hunter et al.	
40		US 60/503,840		Cooper et al.	

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials	Cite No.	Foreign Patent Document <i>Country Code-Number-Kind Code</i> Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
41		EP 0041795 B1	01-16-1985	Ayerst, McKenna And Harrison Inc.	
42		WO 1993/19763	10-14-1993	American Home Products	
43		WO 1999/20261	04-29-1999	Ponikau et al.	
44		WO 1999/22722	05-14-1999	Abbott Laboratories	
45		WO 1999/034830	05-17-1999	Galena	
46		WO 99/37667	07-29-1999	MICROCIDE Pharmaceuticals, INC.	
47		WO 2000/028945	05-25-2000	Ortho-McNeil Pharmaceutical, Inc.	
48		WO 2001/47495	07-05-2001	Pfizer Products Inc.	
49		WO 2002/028387	04-11-2002	Oncopharmaceutical, Inc.	
50		WO 2002/062335	08-15-2002	Vascular Therapies, Inc.	
51		WO 2003/068186	08-21-2003	Lipocene, Inc.	
52		WO 2003/074027	09-12-2003	Novagali Pharma SA	
53		WO 2003/074029	09-12-2003	Vectura Limited	

Examiner Signature	/Zohreh Fay/ (11/11/2011)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T' - Place a checkmark in the box when a continuation or divisional patent application is filed.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/665,203
(Multiple sheets used when necessary)		Filing Date	September 18, 2003
		First Named Inventor	Rong Wen
		Art Unit	1618
SHEET 3 OF 4		Examiner	Zohreh A. Fay
		Attorney Docket No.	MACUS.002A

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	54	WO 2003/090684	11-06-2003	Sun Bow Co., Ltd.		
	55	WO 2004/019904	03-11-2004	Novadel Pharma Inc.		
	56	WO 2004/028477	04-08-2004	Innorx, Inc.		
	57	WO 2004/043480	05-27-2004	Peyman		
	58	WO 2005/051452	06-09-2005	Angiotech International AG		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	59	Akselband, et al. "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts" Transplantation Proceedings. Vol. 23, No. 6. December 1991. p 2833-2836.	
	60	Auricchio, et al. "Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye" Molecular Therapy, July 1, 2002, p 238-242.	
	61	Bainbridge, et al. "Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization." Gene Therapy, 2003; p 1049-1054.	
	62	Humar, et al. " Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling." The FASEB Journal. Vol. 16. June 2002: p771-780.	
	63	Guba, et al. "Rapamycin inhibits tumor growth and metastasis by antiangiogenesis" Chirurgisches Forum 2001. May 1, 2001: p37-39.	
	64	Guba, et al. "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor." Nature Medicine. Vol. 8. No. 2. February 2002. p128-135.	
	65	Treins, et al. "Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway." Journal of Biological Chemistry, August 2, 2002. Vol. 277, No. 31. p. 27975-27981.	
	66	Kuroki, et al. "Rapamycin Inhibits Retinal and Choroidal Neovascularization in Mice." ARVO 2003 Abstract No. 573. May 4, 2003	
	67	Marsland, "The macrolide immunosuppressants in dermatology: mechanisms of action." Eur. J Dermatol. Nov-Dec 2002. p618-22.	
	68	Olsen, et al. "Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization," Arch. Ophthalmol, vol. 112, pp. 1471-1475, Nov. 1994	
	69	RENAU, et al., "Conformationally-Restricted Analogues of Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic & Med. Chem. Letters. (2003) 13:2755-2758.	

Examiner Signature	/Zohreh Fay/ (11/11/2011)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a checkmark in the area when an English language translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application No.</b>	10/665,203
<i>(Multiple sheets used when necessary)</i>		<b>Filing Date</b>	September 18, 2003
		<b>First Named Inventor</b>	Rong Wen
		<b>Art Unit</b>	1618
<b>SHEET 4 OF 4</b>		<b>Examiner</b>	Zohreh A. Fay
		<b>Attorney Docket No.</b>	MACUS.002A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	70	Renau, et al. "Addressing the Stability of C-Capped Dipeptide Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in <i>Pseudomonas aeruginosa</i> ." <i>Bioorganic &amp; Med. Chem. Letters.</i> (2001) 11:663-667	
	71	"Study of possible anticancer drug reveals new mechanism of gene regulation." <i>NewsRx.</i> January 14, 2003	
	72	Shen, et al. "Combined Effect of Cyclosporine and Sirolimus on Improving the Longevity of Recombinant Adenovirus-Mediated Transgene Expression in the Retina." <i>Arch Ophthalmol.</i> July 2001. Vol. 119. p 1033-1043	
	73	Wen, et al. "Rapamycin Inhibits Choroidal Neovascularization" <i>ARVO</i> 2003. Abstract No.3928 May 7, 2003.	

1903476.snd:sad2  
011606

Examiner Signature	/Zohreh Fay/ (11/11/2011)	Date Considered
--------------------	---------------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**T<sup>1</sup>** - Place a checkmark here if reference is CONSIDERED EXCEPT WHERE LINED THROUGH. /ZF/